Today: 2 July 2026
Browse Category

NYSE:LLY 14 January 2026 - 20 January 2026

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

New York, Jan 20, 2026, 10:57 — Regular session Eli Lilly and Company shares nudged up Tuesday following news of a U.S. FDA Breakthrough Therapy designation for its experimental ovarian-cancer drug. The stock traded around $1,040.38, up roughly 0.2%, after starting the session at $1,020 and dipping to a low of $1,019.66. Meanwhile, the SPDR S&P 500 ETF slipped about 1%.
20 January 2026
··
Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

NEW YORK, January 17, 2026, 14:16 EST — The market has closed. U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week.
17 January 2026
······
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

New York, January 16, 2026, 17:39 EST — After-hours Eli Lilly shares ticked up about 0.5%, closing at $1,038.40 in after-hours trading Friday, after swinging between $1,019.00 and $1,049.83 during the session. Internal documents reviewed by Reuters revealed the U.S. FDA has pushed back its target decision date for Lilly’s obesity drug orforglipron to April 10. Holly Fernandez Lynch, a health policy professor at the University of Pennsylvania, noted the delay signals the agency remains cautious, essentially saying: “Hold on, we’re not actually sure this product should be allowed on the market.”
17 January 2026
··
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

New York, Jan 15, 2026, 16:43 — After-hours Eli Lilly and Co shares dropped 3.8% to $1,032.97 in after-hours trading Thursday after Reuters reported the FDA is now aiming for an April 10 decision on Lilly’s experimental obesity drug, orforglipron. The report also revealed delays in other drugs under a new fast-track review program, following safety and efficacy concerns raised by FDA scientists.
15 January 2026
··
Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

New York, Jan 15, 2026, 12:06 — Regular session Eli Lilly and Company shares dropped 4.7% to $1,022.50 on Thursday after Reuters reported that internal documents revealed U.S. regulators delayed a decision on the drugmaker’s weight-loss pill until April 10. A Lilly spokesperson said approval could still come in the second quarter, aligning with current FDA guidance. Holly Fernandez Lynch, a health-policy professor at the University of Pennsylvania, commented on the FDA’s cautious stance, saying, “Hold on, we’re not actually sure this product should be allowed on the market,” highlighting the agency’s readiness to slow fast-tracked reviews.
15 January 2026
·
Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

New York, Jan 13, 2026, 18:23 EST — After-hours Eli Lilly and Company shares were down 0.4% at $1,077.19 in after-hours trading on Tuesday. The U.S. Food and Drug Administration asked drugmakers to remove suicide-related warnings from labels of GLP-1 weight-loss drugs — medicines that mimic a gut hormone to curb appetite — including Lilly’s Zepbound.
14 January 2026
··
1 … 3 4 5 6 7 … 13

Stock Market Today

  • Cramer’s Top 10: Jobs Miss, Upgrades for Palantir and Airlines, OpenAI’s Government Plan
    July 2, 2026, 9:20 AM EDT. Jim Cramer's July 2 watchlist points to a lighter-than-forecast June jobs report-nonfarm payrolls up just 57,000, well below the 115,000 expected. That pushed Treasury yields lower and futures up. OpenAI is reportedly offering the U.S. government a 5% stake to let it in on AI gains. Palantir saw DA Davidson boost the stock to buy, setting a target for 40% upside. Nvidia is rolling out a model where AI startups get compute power in exchange for a piece of revenue. Meta laid out fresh plans for cloud AI. Honeywell Aerospace, Delta, and United picked up upgrades as supply and fuel costs improved. DuPont's price target saw a small bump.
Go toTop